|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
(1) When men and women were assessed together, the frequencies of the MTHFR C677T and A1298 genotypes or their alleles were not significantly different between controls and co</span>lon cancer or rectal cancer cases.
|
18712959 |
2009 |
|
rs67376798
|
|
|
0.010 |
GeneticVariation |
BEFREE |
5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
|
27122156 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Colon carcinoma BRAF V600E HT29 cells exhibited poor response to radiation compared to BRAF wild-type COLO320 and HCT116 cells.
|
29663854 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Colon carcinoma BRAF V600E HT29 cells exhibited poor response to radiation compared to BRAF wild-type COLO320 and HCT116 cells.
|
29663854 |
2018 |
|
rs1380087059
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A636P is associated with early-onset colon cancer in Ashkenazi Jews.
|
12595050 |
2003 |
|
rs1418586322
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A636P is associated with early-onset colon cancer in Ashkenazi Jews.
|
12595050 |
2003 |
|
rs587781394
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A636P is associated with early-onset colon cancer in Ashkenazi Jews.
|
12595050 |
2003 |
|
rs63750875
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A636P is associated with early-onset colon cancer in Ashkenazi Jews.
|
12595050 |
2003 |
|
rs1443465532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
P125A-endostatin also localised into tumour tissue to a higher degree than the native protein, and displayed greater inhibition of growth of colon cancer in athymic mice.
|
15083196 |
2004 |
|
rs760891242
|
|
|
0.010 |
GeneticVariation |
BEFREE |
P125A-endostatin also localised into tumour tissue to a higher degree than the native protein, and displayed greater inhibition of growth of colon cancer in athymic mice.
|
15083196 |
2004 |
|
rs2032582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
G2677T and C3435T polymorphisms are not associated with colon cancer risk and prognosis in a selected patient population.
|
19192650 |
2009 |
|
rs779066883
|
|
|
0.010 |
GeneticVariation |
BEFREE |
S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer.
|
23693020 |
2013 |
|
rs35301225
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs35301225 in miR-34a was highly associated with a decreased risk of CRC in a Chinese population and might serve as a novel biomarker for colon cancer.
|
28293146 |
2017 |
|
rs187960998
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs187960998 in miR-211 was highly associated with a decreased risk of CC in the Chinese population by deregulating a tumor suppressive gene CHD5.
|
30655677 |
2019 |
|
rs1057519822
|
|
|
0.010 |
GeneticVariation |
BEFREE |
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.
|
31227518 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A colon cancer cell line with RNF43-G659Vfs*41 and BRAF-V600E mutations was sensitive to activation of Wnt/β-catenin signaling.
|
31811196 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A colon cancer cell line with RNF43-G659Vfs*41 and BRAF-V600E mutations was sensitive to activation of Wnt/β-catenin signaling.
|
31811196 |
2019 |
|
rs1801394
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A haplotype of A66G and A1298C polymorphisms, A/A, proved to be protective (OR=0.775; 95% CI=0.603-0.996; p=0.04), whereas haplotype A/G was a risk factor for colon cancer (OR=1.270; 95% CI=1.007-1.602; p=0.04).
|
21438757 |
2011 |
|
rs397507444
|
|
|
0.090 |
GeneticVariation |
BEFREE |
A haplotype of A66G and A1298C polymorphisms, A/A, proved to be protective (OR=0.775; 95% CI=0.603-0.996; p=0.04), whereas haplotype A/G was a risk factor for colon cancer (OR=1.270; 95% CI=1.007-1.602; p=0.04).
|
21438757 |
2011 |
|
rs121913314
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A recent report suggested that the risk of colon cancer is higher for those who carry a C-->T transition mutation on codon 531 (Gln-531-->Amber-531) of src gene.
|
10704743 |
2000 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract Cancers) clinical trial were used to assess differential gene expression between c.1799T>A (p.V600E) BRAF mutant and non-BRAF, non-KRAS mutant cancers (double wild type) and to construct a gene expression-based classifier for detecting BRAF mutant samples with high sensitivity.
|
22393095 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract Cancers) clinical trial were used to assess differential gene expression between c.1799T>A (p.V600E) BRAF mutant and non-BRAF, non-KRAS mutant cancers (double wild type) and to construct a gene expression-based classifier for detecting BRAF mutant samples with high sensitivity.
|
22393095 |
2012 |
|
rs4950928
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant association of SNP in SMAD7 rs4939827 and CHI3L1 rs4950928 was revealed between the rectal cancer and colon cancer patients.
|
26779637 |
2016 |
|
rs1042821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A study was conducted to examine whether MLH1 (-93G>A and Ile219Val) and MSH6 (Gly39Glu) polymorphisms were associated with risk of colon cancer in data from 1609 colon cancer cases and 1972 controls.
|
18523027 |
2009 |
|
rs16892766
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A total of 927 MMR gene mutation carriers (360 MLH1, 442 MSH2, 85 MSH6 and 40 PMS2) from 315 families enrolled in the Colon Cancer Family Registry, were genotyped for the single nucleotide polymorphisms (SNPs): rs16892766 (8q23.3), rs6983267 (8q24.21), rs719725 (9p24), rs10795668 (10p14), rs3802842 (11q23.1), rs4444235 (14q22.2), rs4779584 (15q13.3), rs9929218 (16q22.1), rs4939827 (18q21.1), rs10411210 (19q13.1) and rs961253 (20p12.3).
|
23434150 |
2013 |